SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Company limited by guarantee

Company Registration Number:
13339469 (England and Wales)

Unaudited statutory accounts for the year ended 30 April 2025

Period of accounts

Start date: 1 May 2024

End date: 30 April 2025

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Contents of the Financial Statements

for the Period Ended 30 April 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Directors' report period ended 30 April 2025

The directors present their report with the financial statements of the company for the period ended 30 April 2025

Directors

The directors shown below have held office during the whole of the period from
1 May 2024 to 30 April 2025

Dr Andrew McGovern
John Dennis


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
16 January 2026

And signed on behalf of the board by:
Name: Dr Andrew McGovern
Status: Director

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Profit And Loss Account

for the Period Ended 30 April 2025

2025 2024


£

£
Administrative expenses: ( 3,717 ) ( 16,375 )
Operating profit(or loss): (3,717) (16,375)
Profit(or loss) before tax: (3,717) (16,375)
Profit(or loss) for the financial year: (3,717) (16,375)

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Balance sheet

As at 30 April 2025

Notes 2025 2024


£

£
Current assets
Cash at bank and in hand: 100 100
Total current assets: 100 100
Creditors: amounts falling due within one year: 3 ( 20,192 ) ( 16,475 )
Net current assets (liabilities): (20,092) (16,375)
Total assets less current liabilities: (20,092) ( 16,375)
Total net assets (liabilities): (20,092) (16,375)
Members' funds
Profit and loss account: (20,092) ( 16,375)
Total members' funds: ( 20,092) (16,375)

The notes form part of these financial statements

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Balance sheet statements

For the year ending 30 April 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 16 January 2026
and signed on behalf of the board by:

Name: Dr Andrew McGovern
Status: Director

The notes form part of these financial statements

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 30 April 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Other accounting policies

    The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £. The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 30 April 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 0 0

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Notes to the Financial Statements

for the Period Ended 30 April 2025

3. Creditors: amounts falling due within one year note

2025 2024
£ £
Other creditors 20,192 16,475
Total 20,192 16,475

COMMUNITY INTEREST ANNUAL REPORT

SYNAPSE MEDICAL COMMUNITY INTEREST COMPANY

Company Number: 13339469 (England and Wales)

Year Ending: 30 April 2025

Company activities and impact

The company is still being established and has yet to provide meaningful benefit to the community.

Consultation with stakeholders

No consultation with stakeholders

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
18 December 2025

And signed on behalf of the board by:
Name: Dr Andrew McGovern
Status: Director